Sustainable East Africa Research in Community Health (SEARCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01864603

Recruitment Status : Recruiting

First Posted : May 29, 2013

Last Update Posted : June 9, 2017

See Contacts and Locations

Sponsor:

Collaborators:

Infectious Diseases Research Collaboration, Uganda

Makerere University

Kenya Medical Research Institute

Gilead Sciences

World Bank

National Institute of Allergy and Infectious Diseases (NIAID)

United States President's Emergency Plan for AIDS Relief

Bill and Melinda Gates Foundation

Information provided by (Responsible Party):

University of California, San Francisco

Study Description

Brief Summary:

The SEARCH study aims to test evidenced-based innovative community based interventions that lead to the elimination of HIV in rural communities in East Africa using a multi-disease approach. The first phase of the study will quantify the health, economic and educational impact of early HIV diagnosis using a streamlined and immediate ART (antiretroviral therapy). This first phase will be completed in July 2017. The second phase of the study, will quantify the health, economic and educational impact of targeted Pre-Exposure Prophylaxis (PrEP), targeted HIV testing and targeted care interventions in the context of universal treatment and streamlined care. This second phase will be completed in July 2020. The study intervention is designed to improve the entire continuum of care, to reduce structural barriers for all populations including those most "at risk".

Condition or disease	Intervention/treatment	Phase
HIV Tuberculosis Hypertension Diabetes Maternal Child Health Cost Effectiveness	Other: Universal ART in a streamlined care model Other: Annual Community Health Campaigns Other: Targeted PrEP, Targeted testing, and Targeted care interventions Other: Baseline community-based HIV and multi-disease testing	Not Applicable

Detailed Description:

Study Design


Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	340000 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Other
Official Title:	Sustainable East Africa Research in Community Health
Study Start Date :	April 2013
Estimated Primary Completion Date :	July 2020
Estimated Study Completion Date :	July 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Genetic and Rare Diseases Information Center resources: Tuberculosis

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1st: universal test and treat; 2nd: targeted PrEP and cascade Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, targeted HIV testing, and targeted care interventions	Other: Universal ART in a streamlined care model immediate ART start for all HIV+ in community with streamlined care Other: Annual Community Health Campaigns HIV and multi-disease testing for all community members Other: Targeted PrEP, Targeted testing, and Targeted care interventions
Active Comparator: 1st: baseline community testing; 2nd: universal test & treat Intervention arm first phase: baseline community-based HIV and multi-disease testing Intervention arm second: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery	Other: Universal ART in a streamlined care model immediate ART start for all HIV+ in community with streamlined care Other: Baseline community-based HIV and multi-disease testing HIV and multi-disease testing for all community members at baseline only

Arm

Intervention/treatment

Experimental: 1st: universal test and treat; 2nd: targeted PrEP and cascade

Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery

Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, targeted HIV testing, and targeted care interventions

Other: Universal ART in a streamlined care model

immediate ART start for all HIV+ in community with streamlined care

Other: Annual Community Health Campaigns

HIV and multi-disease testing for all community members

Other: Targeted PrEP, Targeted testing, and Targeted care interventions

Active Comparator: 1st: baseline community testing; 2nd: universal test & treat

Intervention arm first phase: baseline community-based HIV and multi-disease testing

Intervention arm second: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery

Other: Universal ART in a streamlined care model

immediate ART start for all HIV+ in community with streamlined care

Other: Baseline community-based HIV and multi-disease testing

HIV and multi-disease testing for all community members at baseline only

Outcome Measures

Primary Outcome Measures :

Cumulative HIV incidence [ Time Frame: 3 years ]
Cumulative 3 year HIV incidence in men and women ages ≥15 years after the start of Phase I intervention.
Cumulative HIV incidence [ Time Frame: 3 years ]
Cumulative 3 year HIV incidence in men and women ages ≥15 years after the start of Phase II intervention (started after 3 years of Phase I).

Secondary Outcome Measures :

Time from diagnosis to AIDS [ Time Frame: 3 and 6 years follow up ]
To compare time from diagnosis to AIDS between the 2 study arms.
Incidence of AIDS-defining events between the study arms [ Time Frame: 3 and 6 years follow up ]
To compare incidence of AIDS-defining events between the study arms.
Total TB and incident TB cases associated with HIV [ Time Frame: 3 and 6 years follow up ]
TTo compare proportion of total TB and incident TB cases associated with HIV between the study arms.
Overall mortality [ Time Frame: 3 and 6 years follow up ]
To compare mortality between the 2 study arms.
Maternal and child mortality [ Time Frame: 3 and 6 years follow up ]
To compare number of maternal and child deaths between the 2 study arms.
Mother to child HIV transmission [ Time Frame: 3 and 6 years follow up ]
To compare mother to child HIV transmission between the 2 study arms.
Population HIV RNA metrics [ Time Frame: 3 and 6 years follow up ]
To compare population HIV RNA metrics between the 2 study arms. HIV metrics include: % with HIV viral suppression; median population HIV RNA level; % HIV RNA by strata i.e. greater than 100,000 vs. <100,000 copies/ml
Association between population HIV RNA metrics and HIV incidence [ Time Frame: 3 and 6 years follow up ]
To determine the association between population HIV RNA metrics and HIV incidence. HIV metrics include: % with HIV viral suppression; median population HIV RNA level; % HIV RNA by strata i.e. greater than 100,000 vs. <100,000 copies/ml
Prevalence of transmitted HIV drug-resistance mutations [ Time Frame: 3 and 6 years follow up ]
To compare the prevalence (number of participants with) of transmitted HIV drug-resistance mutations and pharmacologic measures of ART between the study arms after 3 and 6 years of follow up.
Rates of linkage to and retention in care for HIV [ Time Frame: 3 and 6 years follow up ]
To compare rates of linkage to and retention in care for HIV between the study arms.
Time to ART-initiation [ Time Frame: 3 and 6 years follow up ]
To compare time to ART-initiation between the study arms.
Time to CD4 cell count recovery in Phase I of high CD4 count individuals (CD4>350) [ Time Frame: 3 and 6 years follow up ]
Time to CD4 cell count recovery above 350 after enrollment
Rate of virologic suppression in Phase I of high CD4 count individuals (CD4>350) [ Time Frame: 3 and 6 years follow up ]
Time to viral load measurements below detectable
Treatment-associated toxicities and grade 3 and 4 adverse events in Phase I of high CD4 count individuals (CD4>350) [ Time Frame: 3 and 6 years follow up ]
DAIDS toxicity table symptoms grade 3 or 4
Prevalence of HIV drug resistant mutations after 1 and 2 years of treatment in Phase I of high CD4 count individuals (CD4>350) [ Time Frame: 3 years follow up ]
Number of patients with HIV drug resistant mutations measured after 1 and 2 years of treatment
Cumulative incidence of internally derived HIV infections [ Time Frame: 3 and 6 years follow up ]
To compare the 3 and 6 year cumulative incidence of internally derived HIV infections (infections genetically linked to a prior infection among members of the same community) between the study arms.
Evaluate attitudes of community, patients and providers on care delivery in control and intervention communities [ Time Frame: 3 and 6 years follow up ]
To evaluate attitudes of community, patients and providers on care delivery in control and intervention communities using qualitative focus group interviews
Evaluate implementation of other disease care cascades (hypertension, diabetes, women and children health services) [ Time Frame: 3 and 6 years follow up ]
Uptake of testing, linkage to care and retention to care
Prevalence of complications of diabetes, hypertension and chronic kidney disease (CKD) and to understand the genetic susceptibility of diseases in the study populations. [ Time Frame: 3 and 6 years follow up ]
Number of patients with of complications of diabetes, hypertension and chronic kidney disease (CKD) and to understand the genetic susceptibility of diseases in the study populations in Phase II.
Adherence to PrEP treatment [ Time Frame: 3 years follow up ]
Number of patients who adherence to PrEP treatment
Change in attitudes towards PrEP [ Time Frame: 3 years follow up ]
Qualitative focus group discussions on attitudes toward PrEP
Change in average levels of adults' on- and off-farm employment [ Time Frame: 3 and 6 years follow up ]
To compare the trends in average levels of adults' on- and off-farm employment between the 2 study arms.
Change in average levels of children's on- and off-farm employment [ Time Frame: 3 and 6 years follow up ]
To compare the trends in average levels of children's on- and off-farm employment (child labor) between the 2 study arms.
Change in average levels of children's time allocation to schooling and household activities [ Time Frame: 3 and 6 years follow up ]
To compare the trends in average levels of children's time allocation to schooling and household activities between the 2 study arms.
Change in average asset holdings [ Time Frame: 3 and 6 years follow up ]
To compare the trends in average asset holdings (durable good and livestock) between the 2 study arms.
Change in agricultural output and other economic production [ Time Frame: 3 and 6 years follow up ]
To compare the trends in agricultural output and other economic production, such as fishing, between the 2 study arms.
Change in average levels of cash and in-kind transfers [ Time Frame: 3 and 6 years follow up ]
To compare the trends in average levels of cash and in-kind transfers between the 2 study arms.
Total costs of programming [ Time Frame: 3 and 6 years follow up ]
To compare costs of programming (campaigns, ART) and PrEP (Phase II only) between the study arms: overall; per person identified, linked to care, and started on ART; and per ART-month, CD4 level recovered, and viral load suppressed.
Change in disease burden [ Time Frame: 3 and 6 years follow up ]
To compare disease burden (expressed in disability adjusted life years, DALYs) between the 2 study arms, during and modelled beyond the study period.
Savings from averted disease associated treatment costs [ Time Frame: 3 and 6 years follow up ]
To compare the savings from averted disease associated treatment costs between the 2 study arms.
Occurrence and consequences of false positive HIV diagnosis [ Time Frame: 3 and 6 years follow up ]
To compare the occurrence and consequences of false positive (new) HIV diagnosis
Cost-effectiveness of the intervention [ Time Frame: 3 and 6 years follow up ]
To calculate the incremental cost-effectiveness of the intervention, as net cost per DALY averted.
Evaluate streamlined care of HIV patients [ Time Frame: 3 and 6 years follow up ]
To evaluate streamlined vs. non-streamlined care including time and motion studies for staff and clients (Phase I only).
Number of participants in targeted PrEP vs. country standard PrEP [ Time Frame: 3 years follow up ]
Numbers of participants who accept targeted linkage for PrEP, retention of PrEP treatment, and suppression interventions including time in motion studies for staff and clients (Phase II only).
Adherence to PREP [ Time Frame: 6 months from start of PrEP ]
To compare adherence (proportion of persons starting PrEP who follow-up at routine PrEP visits and proportion of persons with detectable tenofovir in plasma or hair samples) among persons receiving clinic vs community-based delivery
Linkage to care defined as proportion of persons attending an HIV clinic visit by 30 days after HIV test [ Time Frame: 30 days after HIV test ]
To compare linkage to care with or without a phone call from clinic
Linkage to care defined as proportion of persons attending an HIV clinic visit by 30 days after HIV test among adolescents [ Time Frame: 30 days after HIV test ]
To compare linkage to compare among adolescents with or without adolescent navigator
HIV incidence rate [ Time Frame: 3 years follow up ]
To compare HIV incidence rates between base-line and follow-up year 3

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Community Level Inclusion Criteria:

Non-adjacent geopolitical units in south-western and eastern Uganda and western Kenya.
Most recent census population between 9,000 and 11,000 individuals.
Served by an ART providing health center.
Community leader commitment for study participation and implementation.
Accessibility to health center via a maintained transportation route.
Community location with sufficient distance from other potential study communities to limit contamination of intervention or control conditions (buffer zone)

Individual Level Inclusion Criteria:

Residency of individual in community, defined as present in household for at least 6 months of the calendar year.

Community Level Exclusion Criteria:

Presence of ongoing community-based ART intervention strategies that provide treatment outside of the current in-country treatment guidelines.
An urban setting defined as a city with a population of 100,000 or more inhabitants.
Absence of a health center able to provide ART.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01864603

Contacts


Contact: Tamara Clark, MHS		tclark@medsfgh.ucsf.edu

Locations


Kenya
Nyanza Province Kenya	Recruiting
Nyanza Province, Kenya
Principal Investigator: Elizabeth Bukusi, MBChB, PhD
Uganda
Eastern Uganda	Recruiting
Mbale/Tororo region, Uganda
Principal Investigator: Moses Kamya, MBChB, PhD
Southwestern Uganda	Recruiting
Mbarara region, Uganda
Principal Investigator: Moses Kamya, MBChB, PhD

Sponsors and Collaborators

University of California, San Francisco

Infectious Diseases Research Collaboration, Uganda

Makerere University

Kenya Medical Research Institute

Gilead Sciences

World Bank

National Institute of Allergy and Infectious Diseases (NIAID)

United States President's Emergency Plan for AIDS Relief

Bill and Melinda Gates Foundation

Investigators


Study Chair:	Diane Havlir, MD	University of California, San Francisco
Principal Investigator:	Moses Kamya, MBChB, PhD	Makerere University
Principal Investigator:	Maya Petersen, PhD	University of California, Berkeley

More Information

Additional Information:

SEARCH Collaboration website This link exits the ClinicalTrials.gov site

Publications of Results:

Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, Charlebois ED; SEARCH Collaboration. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012;7(8):e43400. Epub 2012 Aug 20.

Thirumurthy H, Chamie G, Jain V, Kabami J, Kwarisiima D, Clark TD, Geng E, Petersen ML, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda. AIDS. 2013 Feb 20;27(4):627-34. doi: 10.1097/QAD.0b013e32835c54d8.

Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013 Feb;56(4):598-605. doi: 10.1093/cid/cis881. Epub 2012 Dec 12. Erratum in: Clin Infect Dis. 2014 Aug 1;59(3):463.

Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, Jain V, Clark TD, Charlebois E, Havlir DV, Kamya M, Geng EH. High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/μL under routine program conditions in Uganda. Clin Infect Dis. 2013 Nov;57(9):1343-50. doi: 10.1093/cid/cit490. Epub 2013 Jul 29.

Jain V, Byonanebye DM, Liegler T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng EH, Charlebois ED, Amanyire G, Kamya MR, Havlir DV; SEARCH Collaboration. Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):327-32. doi: 10.1097/QAI.0000000000000021.

Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Balzer LB, Petersen ML, Thirumurthy H, Charlebois ED, Kamya MR, Havlir DV. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. PLoS One. 2014 Jan 2;9(1):e84317. doi: 10.1371/journal.pone.0084317. eCollection 2014.

Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, Chamie G, Petersen ML, Thirumurthy H, Kamya MR, Charlebois ED, Havlir DV; SEARCH Collaboration. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health. 2013 Dec 9;13:1151. doi: 10.1186/1471-2458-13-1151.

Kotwani P, Balzer L, Kwarisiima D, Clark TD, Kabami J, Byonanebye D, Bainomujuni B, Black D, Chamie G, Jain V, Thirumurthy H, Kamya MR, Geng EH, Petersen ML, Havlir DV, Charlebois ED; SEARCH Collaboration. Evaluating linkage to care for hypertension after community-based screening in rural Uganda. Trop Med Int Health. 2014 Apr;19(4):459-68. doi: 10.1111/tmi.12273. Epub 2014 Feb 3.

Jain V, Byonanebye DM, Amanyire G, Kwarisiima D, Black D, Kabami J, Chamie G, Clark TD, Rooney JF, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda. AIDS. 2014 Sep 24;28(15):2241-9. doi: 10.1097/QAD.0000000000000401.

Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T, Ayieko J, Mwangwa F, Jain V, Byonanebye D, Petersen M, Havlir D, Kamya MR. Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda. PLoS One. 2016 May 27;11(5):e0156309. doi: 10.1371/journal.pone.0156309. eCollection 2016.

Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, Lavoy G, Kwarisiima D, Sang N, Jain V, Thirumurthy H, Liegler T, Balzer LB, Petersen ML, Cohen CR, Bukusi EA, Kamya MR, Havlir DV, Charlebois ED. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016 Mar;3(3):e111-9. doi: 10.1016/S2352-3018(15)00251-9. Epub 2016 Jan 26.

Katrak S, Day N, Ssemmondo E, Kwarisiima D, Midekisa A, Greenhouse B, Kamya M, Havlir D, Dorsey G. Community-wide Prevalence of Malaria Parasitemia in HIV-Infected and Uninfected Populations in a High-Transmission Setting in Uganda. J Infect Dis. 2016 Jun 15;213(12):1971-8. doi: 10.1093/infdis/jiw057. Epub 2016 Feb 10.

Kadede K, Ruel T, Kabami J, Ssemmondo E, Sang N, Kwarisiima D, Bukusi E, Cohen CR, Liegler T, Clark TD, Charlebois ED, Petersen ML, Kamya MR, Havlir DV, Chamie G; SEARCH team. Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya. AIDS. 2016 Sep 10;30(14):2121-6. doi: 10.1097/QAD.0000000000001180.

Jain V, Chang W, Byonanebye DM, Owaraganise A, Twinomuhwezi E, Amanyire G, Black D, Marseille E, Kamya MR, Havlir DV, Kahn JG. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda. PLoS One. 2015 Dec 3;10(12):e0143433. doi: 10.1371/journal.pone.0143433. eCollection 2015.

Balzer LB, Petersen ML, van der Laan MJ; SEARCH Collaboration. Targeted estimation and inference for the sample average treatment effect in trials with and without pair-matching. Stat Med. 2016 Sep 20;35(21):3717-32. doi: 10.1002/sim.6965. Epub 2016 Apr 18.

Thirumurthy H, Jakubowski A, Camlin C, Kabami J, Ssemmondo E, Elly A, Mwai D, Clark T, Cohen C, Bukusi E, Kamya M, Petersen M, Havlir D, Charlebois ED. Expectations about future health and longevity in Kenyan and Ugandan communities receiving a universal test-and-treat intervention in the SEARCH trial. AIDS Care. 2016;28 Suppl 3:90-8. doi: 10.1080/09540121.2016.1178959.

Maeri I, El Ayadi A, Getahun M, Charlebois E, Akatukwasa C, Tumwebaze D, Itiakorit H, Owino L, Kwarisiima D, Ssemmondo E, Sang N, Kabami J, Clark TD, Petersen M, Cohen CR, Bukusi EA, Kamya M, Havlir D, Camlin CS; SEARCH Collaboration. "How can I tell?" Consequences of HIV status disclosure among couples in eastern African communities in the context of an ongoing HIV "test-and-treat" trial. AIDS Care. 2016;28 Suppl 3:59-66. doi: 10.1080/09540121.2016.1168917.

Camlin CS, Ssemmondo E, Chamie G, El Ayadi AM, Kwarisiima D, Sang N, Kabami J, Charlebois E, Petersen M, Clark TD, Bukusi EA, Cohen CR, R Kamya M, Havlir D; SEARCH Collaboration. Men "missing" from population-based HIV testing: insights from qualitative research. AIDS Care. 2016;28 Suppl 3:67-73. doi: 10.1080/09540121.2016.1164806.

Jain V, Petersen ML, Liegler T, Byonanebye DM, Kwarisiima D, Chamie G, Sang N, Black D, Clark TD, Ladai A, Plenty A, Kabami J, Ssemmondo E, Bukusi EA, Cohen CR, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration. Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis. Lancet HIV. 2017 Mar;4(3):e122-e133. doi: 10.1016/S2352-3018(16)30220-X. Epub 2016 Dec 16.

Brown LB, Havlir DV, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED; SEARCH Collaboration. High levels of retention in care with streamlined care and universal test and treat in East Africa. AIDS. 2016 Nov 28;30(18):2855-2864.

Chang W, Chamie G, Mwai D, Clark TD, Thirumurthy H, Charlebois ED, Petersen M, Kabami J, Ssemmondo E, Kadede K, Kwarisiima D, Sang N, Bukusi EA, Cohen CR, Kamya M, Havlir DV, Kahn JG. Implementation and Operational Research: Cost and Efficiency of a Hybrid Mobile Multidisease Testing Approach With High HIV Testing Coverage in East Africa. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):e39-e45.

Brown LB, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Jain V, Ruel T, Clark T, Black D, Chamie G, Bukusi EA, Cohen CR, Kamya MR, Petersen ML, Charlebois ED, Havlir DV. Predictors of Retention in HIV Care Among Youth (15-24) in a Universal Test-and-Treat Setting in Rural Kenya. J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e15-e18. doi: 10.1097/QAI.0000000000001390.

Ssemmondo E, Mwangwa F, Kironde JL, Kwarisiima D, Clark TD, Marquez C, Charlebois ED, Petersen ML, Kamya MR, Havlir DV, Chamie G; SEARCH Collaboration. Implementation and Operational Research: Population-Based Active Tuberculosis Case Finding During Large-Scale Mobile HIV Testing Campaigns in Rural Uganda. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):e46-e50.

Other Publications:

Balzer LB, Petersen ML, van der Laan MJ; SEARCH Consortium. Adaptive pair-matching in randomized trials with unbiased and efficient effect estimation. Stat Med. 2015 Mar 15;34(6):999-1011. doi: 10.1002/sim.6380. Epub 2014 Nov 25.

Camlin CS, Seeley J, Viljoen L, Vernooij E, Simwinga M, Reynolds L, Reis R, Plank R, Orne-Gliemann J, McGrath N, Larmarange J, Hoddinott G, Getahun M, Charlebois ED, Bond V. Strengthening universal HIV 'test-and-treat' approaches with social science research. AIDS. 2016 Mar 27;30(6):969-70. doi: 10.1097/QAD.0000000000001008.

SEARCH Collaboration. Evaluating the feasibility and uptake of a community-led HIV testing and multi-disease health campaign in rural Uganda. J Int AIDS Soc. 2017 Mar 30;20(1):21514. doi: 10.7448/IAS.20.1.21514.


Responsible Party:	University of California, San Francisco
ClinicalTrials.gov Identifier:	NCT01864603 History of Changes
Other Study ID Numbers:	SEARCH
First Posted:	May 29, 2013 Key Record Dates
Last Update Posted:	June 9, 2017
Last Verified:	June 2017

Keywords provided by University of California, San Francisco:


HIV treatment and prevention Tuberculosis Community health campaign PrEP

Additional relevant MeSH terms:


Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections

To Top